Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

254.66

+9.78 (3.99%)

as of Jun 26, 2026, 8:00:00 pm Market Open.

696 watching

Investor Insights

Jun 28, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has garnered a generally positive outlook from various experts, particularly highlighting its strong performance in pharmaceuticals and medical devices after a recent spin-off of its orthopedics division. The company's robust drug pipeline is considered one of the best in the industry, contributing to a resilient stock performance even amidst market volatility. While there is a legal overhang due to ongoing talcum powder lawsuits, experts suggest that this has diminished in significance. The company's valuation appears reasonable, and many experts encourage buying on weakness, reflecting confidence in future growth prospects. Overall, JNJ is seen as a solid investment, especially for those interested in dividend growth and long-term potential.

Consensus

Positive

Valuation

Fair Value

Similar

BUY

A lot of the US big cap stocks have good international exposure. His Fair Market Value is over $125 so there is a lot of potential. The next major resistance point is $73.50.

BUY

US pharmaceuticals are a good defensive place to be.

BUY

US$ decline is positive for this global company. Defensive. Good international diversification. Good revenue streams. Some speculation that they may be an acquirer of Colgate-Palmolive, which could put them under pressure.

BUY

Stock has done absolutely nothing for the last 5 to 7 years. Valuation is somewhere between $85 and $100. Acquisition of Pfizer’s (PFE-N) consumer products division has been adding good value to the company's earnings quality. A good anchor to a portfolio.

WAIT

A sort of a consumer related Dow component stock. These are all getting into trouble, so wait and let this run its course.

BUY ON WEAKNESS

On his watch list. Nice diversified large cap situation. Decent dividend yield. A good mix of business. Would like to buy below $60.

COMMENT

If you were long-term investor, this is a Buy. Have the premiere products. In the near term, it hasn't done very well and probably is not going anywhere, because a number of their drugs have come off patent, had some issues with drug coated stents.

BUY

Thinks the shares should be selling at $75.

BUY

Pharmaceuticals are relatively defensive plays at these prices. All impacted by generic drugs. This company has very little in the way of drug exploration and generic competition. Good consumer-products division.

TOP PICK

Isn't getting much respect. Trading at about 15 X this year's earnings and probably 13.5 X next years. With the strong Cdn$, this is a great time to get into this. Nice dividend. Returning over 20% on equity.

PAST TOP PICK

(A Top Pick July 4/06. Up 6.8%.) An interesting play on demographics. A lot of litigation on drug companies. Pays a good dividend.

BUY ON WEAKNESS

Analysts have target around the $72 area. Current PE is around 16. Earnings are coming out tomorrow, so hold off until these are released. Doesn't like to play them after they've had their first bounce.

BUY

Has under performed since its high in October. Pharmaceutical industry is facing a lot of issues. Trades around 12 X earnings with a yield of about 2.3%. Very well run company. Expecting very good earnings growth. Throws up a lot of free cash flow.

DON'T BUY

Has done better than the other US pharmaceuticals. The sector has not done well. This will be a tough hold because generics will give a lot of competition.

BUY

One of the best consumer product companies with a big medical exposure. Recent study indicated stents are no more effective than drugs, so the stock dropped. A great hedge against a weaker US economy.

Showing 526 to 540 of 626 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Kevin Simpson

Capital Wealth Planning

Bryn Talkington

Requisite Capital Management

Andrey Omelchak

LionGuard Capital Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)